Skip to main content

Sirna Shareholders OK Merck Acquisition; Firm Alters Closing Expectation Date

NEW YORK (GenomeWeb News) — Sirna Therapeutics yesterday said its shareholders have approved Merck’s bid to acquire the company.
 
Sirna said the deal, subject to customary closing conditions, is “expected to close as soon as reasonably practicable.” Earlier in December the company said the acquisition “may close as early as this month.” The deal was originally slated to close by the first quarter of 2007.
  
Merck announced its plans to acquire Sirna for $1.1 billion in cash on Oct. 30. The deal is noteworthy for RNAi technology companies because Sirna, through principally a drug-discovery company, has said in the past that it would license its IP. It is not clear whether they have to date, or whether the Merck acquisition will help or hinder this goal.
 
The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.